Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Mar 2:14:1162703.
doi: 10.3389/fphar.2023.1162703. eCollection 2023.

Editorial: Emerging talents in pharmacology: Drugs outcomes research and policies 2022

Rachel M A Linger  1 , Joseph O Fadare  2 , Ye Shen  3 , Lon J Van Winkle  4   5
Affiliations
Editorial

Editorial: Emerging talents in pharmacology: Drugs outcomes research and policies 2022

Rachel M A Linger et al. Front Pharmacol. .
No abstract available

Keywords: drugs; health; medication; outcomes; pharmacology; policies; students; therapies.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Comment on

  • Editorial on the Research Topic Emerging Talents in Pharmacology: Drugs outcomes research and policies 2022

References

    1. Davies M. J., Glah D., Chubb B., Konidaris G., Mcewan P. (2016). Cost effectiveness of IDegLira vs. Alternative basal insulin intensification therapies in patients with type 2 diabetes mellitus uncontrolled on basal insulin in a UK setting. Pharmacoeconomics 34, 953–966. 10.1007/s40273-016-0433-9 - DOI - PubMed
    1. Ericsson A., Lundqvist A. (2017). Cost effectiveness of insulin degludec plus liraglutide (IDegLira) in a fixed combination for uncontrolled type 2 diabetes mellitus in Sweden. Appl. Health Econ. Health Policy 15, 237–248. 10.1007/s40258-016-0301-y - DOI - PMC - PubMed
    1. Guirguis-Blake J. M., Evans C. V., Perdue L. A., Bean S. I., Senger C. A. (2022). Aspirin use to prevent cardiovascular disease and colorectal cancer: Updated evidence report and systematic review for the US preventive Services Task Force. JAMA 327 (16), 1585–1597. 10.1001/jama.2022.3337 - DOI - PubMed
    1. Hunt B., Mocarski M., Valentine W. J., Langer J. (2017). Evaluation of the long-term cost-effectiveness of IDegLira versus liraglutide added to basal insulin for patients with type 2 diabetes failing to achieve glycemic control on basal insulin in the USA. J. Med. Econ. 20, 663–670. 10.1080/13696998.2017.1301943 - DOI - PubMed
    1. Psota M., Psenkova M. B., Racekova N., Ramirez De Arellano A., Vandebrouck T., Hunt B. (2017). Cost-effectiveness analysis of IDegLira versus basal-bolus insulin for patients with type 2 diabetes in the Slovak health system. Clin. Outcomes Res. 9, 749–762. 10.2147/CEOR.S143127 - DOI - PMC - PubMed

Publication types